Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review

BACKGROUND: Pulmonary invasive mucinous adenocarcinoma (IMA) is a rare variant of lung adenocarcinoma that rarely shows anaplastic lymphoma kinase (ALK) rearrangement. Alectinib (tyrosine kinase inhibitors) has been listed as category 1 recommendations for advanced ALK + NSCLC first-line therapy due...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Rumeng, Shi, Ziling, Duan, Ting, Song, Meijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544264/
https://www.ncbi.nlm.nih.gov/pubmed/34707369
http://dx.doi.org/10.2147/OTT.S334213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544264/
https://www.ncbi.nlm.nih.gov/pubmed/34707369
http://dx.doi.org/10.2147/OTT.S334213

Ejemplares similares